UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001892
Receipt number R000002174
Scientific Title Association between genetic polymorphism and adverse events or effectiveness of S-1-based chemotherapy in patients with gastrointestinal cancer
Date of disclosure of the study information 2009/04/16
Last modified on 2012/10/16 23:14:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Association between genetic polymorphism and adverse events or effectiveness of S-1-based chemotherapy in patients with gastrointestinal cancer

Acronym

TCO-TYMS2009

Scientific Title

Association between genetic polymorphism and adverse events or effectiveness of S-1-based chemotherapy in patients with gastrointestinal cancer

Scientific Title:Acronym

TCO-TYMS2009

Region

Japan


Condition

Condition

gastrointestinal cancer

Classification by specialty

Gastroenterology Hepato-biliary-pancreatic medicine Hematology and clinical oncology
Gastrointestinal surgery Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To investigate the association between genetic polymorphisms and adverse events or effectiveness of S-1-based chemotherapy in patients with gastrointestinal cancer

Basic objectives2

Others

Basic objectives -Others

Phagmacogenetics

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Incidence of adverse events

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients who either completed, currently recieving, or are going to receive S-1-based chemotherapy at Outpatient Oncology Unit, Kyoto University Hospital
2. Patients who have histologically confirmed, unresectable advanced or recurrent gastric, pancreatic, biliary tract or colorectal cancer
3. Patients who provided written informed consent

Key exclusion criteria

1. Patients with at least 6 months S-1 free interval if they were re-treated by S-1-based chemotherapy (e.g. recurrence after adjuvant chemotherapy)
2. Patients who were judged ineligible by investigator

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takafumi Nishimura

Organization

Kyoto University Hospital

Division name

Outpatient Oncology Unit

Zip code


Address

54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Takafumi Nishimura

Organization

Kyoto University Hospital

Division name

Outpatient Oncology Unit

Zip code


Address


TEL


Homepage URL


Email

nisimura@kuhp.kyoto-u.ac.jp


Sponsor or person

Institute

Graduate School of Medicine, Kyoto University

Institute

Department

Personal name



Funding Source

Organization

Taiho Pharmaceutical

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 04 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2009 Year 03 Month 13 Day

Date of IRB


Anticipated trial start date

2009 Year 04 Month 01 Day

Last follow-up date

2011 Year 03 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

TYMS, UMPS, DPYD, MTHR


Management information

Registered date

2009 Year 04 Month 16 Day

Last modified on

2012 Year 10 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002174


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name